glp 1 patents GLP-1 Patent Landscape: Who Leads the Innovation Race Pharma or Food? June 2024 Patent Highlights: GLP-1R
Description
In patients with both diabetes and chronic kidney disease, Jardiance lowered cardiovascular death rates, strengthening its position as a preferred SGLT2 inhibitor in this population
Aucatzyl is the first CAR T therapy to be approved without a Risk Evaluation Mitigation Strategy program requirement
54 GLP-1-Am (12, -Glu-palm), GLP-1-Am (17, -Glu-palm), and liraglutide-Am (GLP-1-Am (20, -Glu-palm)) ThT curves all show no or only a very short lag phase
Likewise, SGLT-2is may favor a eubiotic state, which is associated with better renal and metabolic outcomes
Peer review Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work
